Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$27,000.00

Characterizing heme oxygenase-1 dependency in SMARCA4-mutant cancers

FY 2024-25

Summary
Cancer is the leading cause of death in Canada and in 2023, it was estimated that 45% of Canadians would receive a cancer diagnosis in their lifetime. By definition, cancer involves alterations to genes, which are made of DNA. The gene SMARCA4 regulates gene expression by modifying DNA structure, but is inactivated in 10% of non-small cell lung cancers (NSCLC) and 100% of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).Our lab previously identified a unique vulnerability of NSCLC and SCCOHT cancer cells that lack SMARCA4: deactivating a protein called heme oxygenase-1 (HO-1). Knocking out HO-1 kills SMARCA4-deficient cancers but preserves healthy, SMARCA4-proficient cells, which presents a potential therapeutic approach to these types of cancers. However, the mechanism of this selective toxicity is still unknown - why does deactivating HO-1 only affect cancer cells lacking functional SMARCA4? This project aims to answer this.The function of HO-1 is to degrade heme. Without it, heme accumulates and can be toxic for several potential reasons: i) excessive production of harmful chemicals called reactive oxygen species (ROS); ii) damage to DNA structure; or iii) damage to a part of the cell called the endoplasmic reticulum (ER). As ROS overproduction has already been ruled out in previous experiments, we will evaluate DNA and ER damage and also test a suite of genes in a genetic screen to identify other potential mechanisms of selective toxicity.This project will enhance our understanding of SMARCA4-deficient cancers on the molecular scale and identify their vulnerabilities that can be exploited therapeutically. It also contributes to an ongoing project to develop drugs targeting HO-1 to potentially fill a gap in currently available cancer treatments.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529634
Name
LindenSmith Zoë
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing heme oxygenase-1 dependency in SMARCA4-mutant cancers
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Genomics; Cytotoxicity; Genetic Screen; Heme-Oxygenase 1; Hmox1; Hypercalcemic Type; Non Small Cell Lung Cancer; Small Cell Carcinoma Of The Ovary; Smarca4; Swi/Snf; Synthetic Lethality
Abstract
Cancer is the leading cause of death in Canada and in 2023, it was estimated that 45% of Canadians would receive a cancer diagnosis in their lifetime. By definition, cancer involves alterations to genes, which are made of DNA. The gene SMARCA4 regulates gene expression by modifying DNA structure, but is inactivated in 10% of non-small cell lung cancers (NSCLC) and 100% of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).Our lab previously identified a unique vulnerability of NSCLC and SCCOHT cancer cells that lack SMARCA4: deactivating a protein called heme oxygenase-1 (HO-1). Knocking out HO-1 kills SMARCA4-deficient cancers but preserves healthy, SMARCA4-proficient cells, which presents a potential therapeutic approach to these types of cancers. However, the mechanism of this selective toxicity is still unknown - why does deactivating HO-1 only affect cancer cells lacking functional SMARCA4? This project aims to answer this.The function of HO-1 is to degrade heme. Without it, heme accumulates and can be toxic for several potential reasons: i) excessive production of harmful chemicals called reactive oxygen species (ROS); ii) damage to DNA structure; or iii) damage to a part of the cell called the endoplasmic reticulum (ER). As ROS overproduction has already been ruled out in previous experiments, we will evaluate DNA and ER damage and also test a suite of genes in a genetic screen to identify other potential mechanisms of selective toxicity.This project will enhance our understanding of SMARCA4-deficient cancers on the molecular scale and identify their vulnerabilities that can be exploited therapeutically. It also contributes to an ongoing project to develop drugs targeting HO-1 to potentially fill a gap in currently available cancer treatments.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
LindenSmith, Zoë
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~